Literature DB >> 21720807

Growth-inhibitory effect of neurotrophin-3-secreting adipose tissue-derived mesenchymal stem cells on the D283-MED human medulloblastoma cell line.

Young-Hoon Kim1, Seung Hee Cho, Soo Jung Lee, Seung Ah Choi, Ji Hoon Phi, Seung-Ki Kim, Kyu-Chang Wang, Byung-Kyu Cho, Chae-Yong Kim.   

Abstract

Medulloblastoma (MBL), the most common malignant pediatric brain tumor, is incurable in about one-third of patients and can lead to long-term disabilities despite current multimodal treatments. The purpose of this study was to demonstrate in vitro biological effects of neurotrophins-3 (NT-3) on MBL cells and to evaluate the growth-inhibitory effect of neurotrophin-3 (NT-3)-secreting stem cells on tumor cells. We confirmed by western blotting that D283-MED cells express tyrosine kinase C, a specific receptor for NT-3. Analyzing the biological effects of NT-3 on MBL cells, we evaluated autophagy, apoptosis, senescence, and differentiation of tumor cells with NT-3. The NT-3 induced a concentration-dependent increase in apoptosis in the tumor cell line (P < 0.001). The high concentrations of NT-3 increased the expression of class III β-tubulin (P < 0.001) and decreased the expression of Nestin (P < 0.05). NT-3-secreting stem cells were produced by nucleofecting pIRES2.EGFP-NT3 into human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) and their tropic property toward MBL cells was confirmed by migration assay. Double-layered co-culture experiments with the NT-3-secreting hAT-MSCs and D283-MED MBL cells were performed, and NT-3-induced cell death was studied by 3-(4,5-dimethylathiazol-2-yl)-2,5-dephenyl-tetrazolium bromide (MTT) assay. Consequently, the high concentrations of NT-3-secreting hAT-MSCs significantly (P < 0.05) increased the death of D283-MED cells in vitro. The present study demonstrated that both apoptotic cell death and neuronal differentiation of tumor cells were the mechanisms of growth-inhibitory effect of NT-3-secreting hAT-MSCs on MBL cell line.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720807     DOI: 10.1007/s11060-011-0656-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  39 in total

1.  Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.

Authors:  U Herrlinger; C Woiciechowski; M Sena-Esteves; K S Aboody; A H Jacobs; N G Rainov; E Y Snyder; X O Breakefield
Journal:  Mol Ther       Date:  2000-04       Impact factor: 11.454

2.  Generation of neural progenitor cells from whole adult bone marrow.

Authors:  Peter Kabos; Moneeb Ehtesham; Andrea Kabosova; Keith L Black; John S Yu
Journal:  Exp Neurol       Date:  2002-12       Impact factor: 5.330

3.  Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors.

Authors:  M A Grotzer; A J Janss; P C Phillips; J Q Trojanowski
Journal:  Klin Padiatr       Date:  2000 Jul-Aug       Impact factor: 1.349

Review 4.  Medulloblastoma: clinical and biologic aspects.

Authors:  R J Packer; P Cogen; G Vezina; L B Rorke
Journal:  Neuro Oncol       Date:  1999-07       Impact factor: 12.300

5.  Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors.

Authors:  Y Muragaki; T T Chou; D R Kaplan; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

6.  TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.

Authors:  M A Grotzer; A J Janss; K Fung; J A Biegel; L N Sutton; L B Rorke; H Zhao; A Cnaan; P C Phillips; V M Lee; J Q Trojanowski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

7.  Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.

Authors:  H S Friedman; P C Burger; S H Bigner; J Q Trojanowski; C J Wikstrand; E C Halperin; D D Bigner
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

8.  Results of radiosurgery in the management of recurrent and residual medulloblastoma.

Authors:  S J Patrice; N J Tarbell; L C Goumnerova; D C Shrieve; P M Black; J S Loeffler
Journal:  Pediatr Neurosurg       Date:  1995       Impact factor: 1.162

9.  Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.

Authors:  Alice B Brown; Wendy Yang; Nils O Schmidt; Rona Carroll; Kim K Leishear; Nikolai G Rainov; Peter M Black; Xandra O Breakefield; Karen S Aboody
Journal:  Hum Gene Ther       Date:  2003-12-10       Impact factor: 5.695

Review 10.  Class III beta-tubulin in human development and cancer.

Authors:  Christos D Katsetos; Mary M Herman; Sverre J Mörk
Journal:  Cell Motil Cytoskeleton       Date:  2003-06
View more
  4 in total

Review 1.  Adipose tissue stem cells: the great WAT hope.

Authors:  William P Cawthorn; Erica L Scheller; Ormond A MacDougald
Journal:  Trends Endocrinol Metab       Date:  2012-03-12       Impact factor: 12.015

Review 2.  Human-derived normal mesenchymal stem/stromal cells in anticancer therapies.

Authors:  Cheng Zhang; Shi-Jie Yang; Qin Wen; Jiang F Zhong; Xue-Lian Chen; Andres Stucky; Michael F Press; Xi Zhang
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

3.  Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways.

Authors:  Zhangshuo Yang; Hao Zhang; Maohui Yin; Zhixiang Cheng; Ping Jiang; Maohui Feng; Bo Liao; Zhisu Liu
Journal:  Int J Biol Sci       Date:  2022-10-03       Impact factor: 10.750

Review 4.  The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury.

Authors:  Christopher S Ahuja; Andrea Mothe; Mohamad Khazaei; Jetan H Badhiwala; Emily A Gilbert; Derek van der Kooy; Cindi M Morshead; Charles Tator; Michael G Fehlings
Journal:  Stem Cells Transl Med       Date:  2020-07-21       Impact factor: 6.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.